Moreover, even though molecular tumor properties are increasingly recognized as crucial determinants of clinical outcome in both EGFR+ and ALK+ NSCLC,4,20, 21, 22 their potential importance for management of brain disease remains unclear. This evidence concerns the gene ALK and neoplasm.